



Early Diagnosis, Pathogenesis and Treatment Strategies of Atrial Fibrillation

Guest Editors:

Dr. José-Luis Clúa-Espuny

Primary Health-Care Centre,
Institut Catala de la Salut,
Primary Care Service (SAP) Terres
de l'Ebre, 43500 Tortosa, Spain

Dr. Silvia Reverté-Villarroya

Advanced Nursing Research
Group, Medicine and Health
Sciences, University Rovira i
Virgili, 43002 Tarragona, Spain

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

Atrial fibrillation (AF) is a common cardiac arrhythmia, the treatment strategies for which vary depending on the underlying causes and severity of the condition.

This Special Issue will provide an overview of the pathogenesis of AF, and the complex interplay between various mechanisms involved in its initiation, early diagnosis, and management. This issue will also review the different strategies for detecting individuals at high risk for AF; the management and treatment of AF diagnosed early using methods such as artificial intelligence and digital devices; pharmacological therapies such as antiarrhythmic drugs and rate control agents; non-pharmacological interventions such as catheter ablation and electrical cardioversion; and stroke prevention strategies such as anticoagulation therapy. Moreover, we will discuss the challenges and limitations of early diagnosis, as well as current treatment options, and highlight emerging strategies that may offer new approaches to managing AF.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)